Loading company…
MDimune develops a cell-derived drug delivery platform for biotechnology and pharmaceutical companies.
Founded in 2015 and based in Seoul, South Korea, MDimune develops BioDrone, a drug delivery platform using vesicles derived from immune or stem cells. The platform is intended to deliver medicines to targeted areas and support development of treatments for cancer and other diseases. In August 2019, the company raised KRW 10.7 billion in Series B funding from DAYLI Partners, InterValue Partners, KClavis Investment and others.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in